Extended Data Fig. 6. Identification of CCL25 as an essential chemokine controlling ILC3 motility.
a, Intestinal ILC3s were imaged in RR22 mice using intravital imaging for one hour. Then, mice were injected i.v. with a combination of blocking monoclonal antibodies (anti-CXCL12, anti-CXCL16, and anti-CCL21) and subsequently imaged for 2 hours. Individual tracks of intestinal ILC3s before (−60–0 min), 1 h (0–60 min) and 2 h (60–120 min) after blocking antibodies injection. Mean speed, arrest coefficient and straightness ratio of intestinal ILC3s at indicated timepoints after blocking antibodies injection. Results in (a) are from at least five movies per condition obtained in two independent experiments (n = 129, n = 100, and n = 184 ILC3s for 0 h, 1 h and 2 h, respectively). b, Individual tracks of intestinal NKp46+Il22+ ILC3s before (−60–0 min), 1 h (0–60 min) and 2 h (60–120 min) after CCL25 Ab injection and 5 h after Flag injection. Mean speed, arrest coefficient and straightness ratio of intestinal NKp46+ Il22+ ILC3s at indicated timepoints after CCL25 Ab injection. Results in (b) are from at least five movies per condition obtained in two independent experiments (n = 78, 0 h; n = 50, 1 h; n = 49, 2 h). Each bar corresponds to the mean ± s.e.m of the values obtained (ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001; one-way ANOVA; exact P values are provided in the source data). RR22, Rag2−/−RorcGFPIl22TdT; CCL25 Ab, CCL25 blocking antibody; Flag, Flagellin.